标题
Drug safety evaluation of lenvatinib for thyroid cancer
作者
关键词
-
出版物
Expert Opinion On Drug Safety
Volume 14, Issue 12, Pages 1935-1943
出版商
Informa Healthcare
发表日期
2015-10-21
DOI
10.1517/14740338.2015.1102883
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
- (2015) Maria E. Cabanillas et al. CANCER
- Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit
- (2015) Rashmi R. Shah et al. DRUG SAFETY
- Lenvatinib in Radioiodine-Refractory Thyroid Cancer
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials
- (2014) Wei-Xiang Qi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers
- (2014) Robert C. Shumaker et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms
- (2014) Sariah Liu et al. CANCER TREATMENT REVIEWS
- Role of Salvage Targeted Therapy in Differentiated Thyroid Cancer Patients Who Failed First-Line Sorafenib
- (2014) Ramona Dadu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Risks of Proteinuria Associated with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis
- (2014) Ze-Feng Zhang et al. PLoS One
- Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer
- (2014) Jolanta Krajewska et al. Expert Opinion on Orphan Drugs
- Definition and management of radioactive iodine-refractory differentiated thyroid cancer
- (2014) Martin Schlumberger et al. Lancet Diabetes & Endocrinology
- A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
- (2013) Ana M. Molina et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
- (2013) Kiyoshi Okamoto et al. CANCER LETTERS
- Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis
- (2013) Rafael Selbach Scheffel et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Long-Term Cardiovascular Mortality in Patients With Differentiated Thyroid Carcinoma: An Observational Study
- (2013) Esther N. Klein Hesselink et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of TKI-induced diarrhea in cancer patients
- (2013) Joanne M. Bowen Current Opinion in Supportive and Palliative Care
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
- (2012) D S Boss et al. BRITISH JOURNAL OF CANCER
- Model-based treatment optimization of a novel VEGFR inhibitor
- (2012) Ron J. Keizer et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis
- (2012) Wei-Xiang Qi et al. INTERNATIONAL JOURNAL OF CANCER
- Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
- (2012) Fabio A.B. Schutz et al. JOURNAL OF CLINICAL ONCOLOGY
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
- (2012) Sophie Leboulleux et al. LANCET ONCOLOGY
- The Impact of Distant Metastases at Presentation on Prognosis in Patients with Differentiated Carcinoma of the Thyroid Gland
- (2012) Iain J. Nixon et al. THYROID
- American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
- (2012) Robert C. Smallridge et al. THYROID
- E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
- (2011) Hilary Glen et al. BMC CANCER
- Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
- (2011) K. Yamada et al. CLINICAL CANCER RESEARCH
- ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer
- (2011) M Schlumberger et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Fatal Heart Failure After a 26-Month Combination of Tyrosine Kinase Inhibitors in a Papillary Thyroid Cancer
- (2011) Marie-Elisabeth Toubert et al. THYROID
- A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
- (2010) Ron J. Keizer et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
- (2010) Keith C Bible et al. LANCET ONCOLOGY
- Tyrosine kinase inhibitors and the thyroid
- (2009) Steven I. Sherman BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase II Trial of Sorafenib in Metastatic Thyroid Cancer
- (2009) Richard T. Kloos et al. JOURNAL OF CLINICAL ONCOLOGY
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
- (2009) David S. Cooper et al. THYROID
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase
- (2008) J. Matsui et al. CLINICAL CANCER RESEARCH
- Chemotherapy with Doxorubicin in Progressive Medullary and Thyroid Carcinoma of the Follicular Epithelium
- (2008) A. Matuszczyk et al. HORMONE AND METABOLIC RESEARCH
- Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
- (2008) Ezra E.W. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Sorafenib in Advanced Thyroid Cancer
- (2008) Vandana Gupta-Abramson et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started